1 Division of Nephrology and Comprehensive Transplant Center, Ohio State University, Columbus, OH.
2 Division of Hematology and Oncology, Ohio State University, Columbus, OH.
3 Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA.
Received 23 July 2018. Revision received 9 October 2018.
Accepted 10 October 2018.
P.S., J.V.V., J.P., D.P., B.R., and T.E.P. declare no conflicts of interest. T.O. declares conflicts of interest with Pfizer, Bristol-Myers Squibb, and Regeneron.
P.S., J.V.V., J.P., T.O., D.P., B.R., and T.P. contributed to the design, analysis, and interpretation of data. P.S., J.V.V., J.P., T.O., D.P., B.R., and T.P. wrote, reviewed, and approved the article.
The case study is exempt from IRB approval.